Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AGEN Inc.

Division of Agen Biomedical Ltd.

Latest From Facet Biotech Corp.

Heightened Standards Proposed For Finger-Prick Devices

FDA issued proposed orders to remove the 510(k) exemption and establish special controls for most blood lancets, and require PMAs for one super-risky category of the finger-prick devices. The goal is to reduce infectious disease transmission.

Medical Device Regulation

ASH data to watch: GlycoMimetics, Ambit, Emergent

Stock prices for Ambit Biosciences and Emergent BioSolutions dipped after abstracts for their data presentations at the upcoming American Society of Hematologists (ASH) Annual Meeting and Exposition became public on 7 November, and GlycoMimetics postponed its initial public offering on 8 November, but all three companies have data worth watching when ASH welcomes doctors and scientists to New Orleans from 7 to 10 December.

Cardiovascular Infectious Diseases

FDA Panel Recommends Upclassification of Blood Lancets

The General and Plastic Surgery Devices advisory panel strongly supported FDA’s proposal to reclassify blood lancets from class I to class II or III during a June 26 meeting. Panelists raised concerns, in particular, about the safety of multi-use blood lancets.

Medical Device Regulation

Theravance To Split Into A Royalty Play and An R&D Company

With a pair of PDUFA dates this year, Theravance is thinking ahead how to pass potential royalties to investors while continuing to fund its pipeline. The biopharma said it would separate into two public companies: a royalty play to return cash to shareholders and an R&D pipeline story.

BioPharmaceutical Business Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register